Skip to content

Facial analysis in acromegaly: a cross sectional study of persistent craniofacial changes after remission.

Facial analysis in acromegaly: a cross sectional study of persistent craniofacial changes after remission. - Facial analysis in acromegaly.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON35636
Enrollment
20
Registered
2011-12-07
Start date
2012-01-23
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

weke delen van het gelaat benign pituitary tumor that produces growth-hormone growth-hormone producing pituitary adenoma

Interventions

None listed

Sponsors

Universitair Medisch Centrum Sint Radboud
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: The subjects are adult patients with acromegaly, who are in remission with only transsphenoidale pituitary surgery treatment, and still visit the outpatient clinic of the department of Endocrinology. Remission is defined as disappearance of clinical symptoms of active GH hypersecretion with in addition normal IGF-1 levels (

Exclusion criteria

Exclusion criteria: Patients may not participate in the study if they are pregnant or received oral/maxillofacial surgical treatment in the past.

Design outcomes

Primary

MeasureTime frame
The comparison of cephalometricand facial analyses of both 3D stereophotography and 3D cone beam CT data in patients with acromegaly and healthy subjects.Furthermore, the average face scan be computed based on the 3D photographs acquired in this study. An average face will be computed for acromegalic patients and healthy subjects. After computation, the average faces can be compared to analyze the overall differences in facial differences between both groups.

Secondary

MeasureTime frame
The following parameters will also be collected: sex, date of birth, length, weight, oral/maxillofacial surgical treatment in the past, pre-operative IGF-1, GH and oral glucose tolerance test, pituitary MRI results (micro/macro adenoma), date of diagnosis, date of operation, post-operative IGF-1, GH and oral glucose tolerance test, duration of follow-up, last IGF-1 result and presence of hypopituitarism.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)